Collectively, these results suggest that PXL770 treatment can have beneficial effects to ameliorate the proinflammatory phenotype of ALD diseased cells, in line with the well-known anti-inflammatory properties of AMPK activation. The gene discussed is PRKAA1; the disease is adrenoleukodystrophy.